Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2004

View Archived Issues

St. John's wort and hypericin may prevent diabetic and premature retinopathy

Synergistic effects of atorvastatin and glatiramer in experimental autoimmune encephalomyelitis

Researchers suggest an interaction between ApoE genotype, statins and risk for AD

Novel antiparkinsonian agent with improved blood-brain barrier penetrability

Antiretroviral spermicide WHI-07 effective against FIV transmission in domestic cats

Analgesic effects of duloxetine in patients with DNP

Curcumin for cystic fibrosis therapy

KR-31378 beneficial in focal ischemia, probably due to antioxidant properties

Prostaglandin derivative DE-085 increases retinal blood flow

Two series of SSRIs and their use in premature ejaculation and other disorders

Genelabs describes a series of DNA-targeted antifungal/antibacterial agents

Arrow Therapeutics claims 1,4-benzodiazepine-based anti-RSV agents

German scientists identify an antitumor and anti-HIV compound from Penicillium species

Novel Pin1 inhibitors prepared and tested at Jerini

Novel 5-HT6 receptor ligands described by Roche researchers

HMGB1: a therapeutic target molecule for chronic arthritis and sepsis

VP-025 reduces perinatal hypoxic-ischemic brain injury in rat study

FDA Advisory Committee gives negative opinion for Genasense

Eligard launched in Germany

Zorbtive launched for short bowel syndrome

4SC and Serono enter DHODH inhibitor agreement

FDA Advisory Committee does not recommend approval of RSR-13

PRO-140 viral entry inhibitor enters phase I

NCI-sponsored study evaluates GTI-2040 combination therapy for colon cancer

Voluntary withdrawal of marketing authorization for Tikosyn in E.U.

CPMP recommends lifting suspension of marketing authorization for tolcapone

Developments in Kucera's antiviral programs

European pivotal phase III trial for rhC1INH commences

PYM-50018 successfully completes phase I

Teriparatide reported to reduce back pain in postmenopausal osteoporosis

Exenatide improves glycemic control in diabetics receiving metformin and/or sulfonylureas